Regulatory approval

Published by the Health Service Executive. Approved

First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pembrolizumab - ODMS; Carboplatin, Paclitaxel - N/A

Citation

Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy, 2025, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6879/712_V3a_Nivolumab_ipili_plus_PACLitaxel-CARBOplatin.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2022-03-01	Health Service Executive	Indication approved for reimbursement.